Concentra Biosciences is living up to its reputation of buying beleaguered biotechs, this time swooping in to grab iTeos ...

In May, biotech iTeos Therapeutics decided to close down after being abandoned by GSK over the disappointing mid-stage ...

WATERTOWN, Mass. and GOSSELIES, Belgium, July 21, 2025 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (“iTeos”) (Nasdaq: ITOS) today announced that it has entered into a definitive merger agreement ...

US biotech iTeos Therapeutics yesterday announced that it has entered into a definitive merger agreement Concentra ...

Immuno-oncology drug developer iTeos Therapeutics ( NASDAQ: ITOS) on Monday said it has entered into an agreement to be acquired by Concentra Biosciences for $10.047 in cash per share plus a ...

While we acknowledge the potential of iTeos Therapeutics, Inc. (NASDAQ:ITOS) as an investment, our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns ...

Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of iTeos Therapeutics, Inc. (NASDAQ: ITOS) to Concentra Biosciences, LLC is fair to iTeos shareholders. Under the terms ...

ITeos Therapeutics, Inc. (NASDAQ:iTOS) is not on our list of 30 Most Popular Stocks Among Hedge Funds. As per our database, 29 hedge fund portfolios held iTeos Therapeutics, Inc. (NASDAQ:ITOS) at the ...

Detailed price information for Iteos Therapeutics Inc (ITOS-Q) from The Globe and Mail including charting and trades.

Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or ...

CEO Emma Walmsley maintained that continued investment in the U.S. is a priority for the pharma to ensure its medicines for ...

GSK has become the latest drugmaker to run into difficulties in developing a drug targeting the immune checkpoint receptor ...